Calls are growing for U.S. authorities to commute the death sentence of Tennessee death row inmate Christa Pike.The UN human rights chief and nine independent rights experts ...
Enterprise software veteran to lead Tacton's united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutio ...
The euro weakened against other major currencies in the European session on Friday, due to growing budgetary concerns, French bond rates have surged to the highest level since ...
The Healthspan Action Coalition (HSAC) today announced a strategic international collaboration with a coalition of prominent Italian organizations ...
LBank Exchange, a leading global cryptocurrency trading platform, listed ATS (Atlas) at 06:00am on Oct 2, 2026 (UTC).ATS (Atlas) ...
KBRA UK (KBRA) assigns preliminary ratings to five classes of refinancing Notes issued by RRE 11 Loan Management DAC, a cash flow collateralised loan obligation (CLO) backed primarily by a diversified ...
The US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A is still ongoing. The FDA has not communicated a new timeline for regula ...
KØBENHAVN, DK / ACCESS Newswire / October 2, 2026 / FluoGuide A/S (STO:FLUO) FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a colla ...
After plummeting early in the day, the price of crude oil has regained some ground over the course of the trading session on Friday but remains sharply lower.Crude oil for ...
TORONTO, ON / ACCESS Newswire / October 2, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-bas ...
Qben Construction AB, part of Qben Infra AB (publ) ("Qben Infra" or the "Company"), has entered into an agreement to sell all shares in Team Bygg AS ("Team Bygg") to Emercor AS ("Emercor" or the "Buye ...
Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipamAn interim 18-month analysis of an ongoing open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results